Griffin Securities Announces Investment Opinion on Targeting Cancer Stem Cells
09 Octubre 2009 - 8:11AM
Business Wire
Griffin Securities (“Griffin”), a research-driven investment
banking firm, has released an industry report on the subject of
targeting cancer stem cells (CSCs). The stem cell hypothesis offers
a rational approach to preventing, diagnosing, and treating
malignant growth. Covered in the report are five classes of drugs
nearing the Phase II clinical trial that provides human proof-of
concept data, a crucial stage of development: Notch signaling,
P13k/akt pathway, immunotherapeutics, molecular chaperons, and
hedgehog signaling.
Companies highlighted in the write up include: Bristol Myers
Squibb Co. (Public), Calistoga Pharmaceuticals (private), Champions
Biotechnology Inc. (Public, OTC:CSBR), Curis, Inc. (Public),
Exelixis, Inc., Genentech (private), ImmunoCellular Therapeutics,
Ltd. (Public), Infinity Pharmaceuticals Inc. (Public), Keryx
Biopharmaceuticals (Public, MabCure Inc (Public, OTC:MBCI), Merck
& Co., Inc. (Public), Myriad Pharmaceuticals, Inc. (Public),
Novartis AG (ADR) (Public), OncoMed Pharmaceuticals (private),
Oncothyreon Inc. (Public), Pfizer Inc. (Public), Rexahn
Pharmaceuticals, Inc. (Public), Roche Holding Ltd. (ADR) (Public),
Synta Pharmaceuticals Corp. (Public), and Trojantec (Private).
The report can be downloaded by clicking on the link below:
http://www.griffinsecurities.com/pdf/Industry_Reports/Griffin_Industry_Report_-_Targeting_Cancer_Stem_Cells_14Sep09.pdf
About Griffin
Securities
Griffin Securities is a research-driven investment banking firm
providing corporate finance, merger & acquisitions, brokerage,
and investment opportunities for institutional, corporate, and
private clients. The firm is a member of the Financial Industry
Regulatory Authority (FINRA) (www.finra.org) and the Securities
Investor Protection Corporation (SIPC) (www.sipc.org). Griffin
Securities is headquartered in New York City and has no other
domestic or international affiliates or subsidiaries.
FORWARD-LOOKING STATEMENTS: The Report contains forward-looking
statements, which involve risks and uncertainties. Actual results
may differ significantly from such forward-looking statements.
Factors that might cause such a difference include, but are not
limited to, those discussed in the “Risk Factors” section in the
SEC filings available in electronic format through SEC Edgar
filings at www.sec.gov on t
MabCure (CE) (USOTC:MBCI)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
MabCure (CE) (USOTC:MBCI)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
